Fig. 4. MiR-590 represses EHD1-mediated erlotinib resistant and CSC characteristics.

a miR-590 was measured by real-time RT-PCR in PC9/GR, and PC9/GR cells with expressing miR-590 (PC9/GR/miR-590) and PC9/GR/miR-NC, respectively. b Indicated cells were untreated or treated with erlotinib and analysed for cell viability by CCK assay. c The effects of miR-590 expression mediated mRNA expression of KLF4, SOX2 and Nanog. d The effects of miR-590 expression mediated CD133+ cells. e The effects of transfection EHD1 in miR-590-overexpressing PC9/GR cells on CSC phenotypes. f The ability to form spheres and g erlotinib sensitivity. h Effects of miR-590 overexpression with or without transfection EHD1 on the tumour growth of PC9/GR cells were evaluated in the NOD/SCID mice with xenografts after treatment with erlotinib for 2 weeks. *P < 0.05